Summary of Key Information:
Reporting Period: Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting - Financial Results and Director Appointment
Date of Board Meeting / Approval: July 24, 2026 (commenced at 10:15 am, concluded at 13:50 pm)
Audit Opinion: Clean opinion - limited review reports do not have any modification
Auditor's Comment: No qualifications or modifications affecting earnings quality, internal controls, or going concern
Key Financial Highlights [₹ crore]
Standalone Results:
Revenue from Operations: ₹1,588.60 (Q1 FY27) vs ₹1,304.56 (Q1 FY26) - 21.8% YoY increase
Total Income: ₹1,614.91 (Q1 FY27) vs ₹1,333.53 (Q1 FY26)
Net Profit: ₹201.03 (Q1 FY27) vs ₹97.74 (Q1 FY26) - 105.6% YoY increase
EPS: ₹68.28 (Basic and Diluted)
Quarterly comparison:
- Revenue from Operations: ₹1,588.60 (Q1 FY27) vs ₹1,497.93 (Q4 FY26)
- Net Profit: ₹201.03 (Q1 FY27) vs ₹203.84 (Q4 FY26)
Full year reference (FY26):
- Revenue from Operations: ₹5,563.57
- Net Profit: ₹595.04
Consolidated Results:
Revenue from Operations: ₹1,847.95 (Q1 FY27) vs ₹1,478.00 (Q1 FY26) - 25.0% YoY increase
Total Income: ₹1,881.26 (Q1 FY27) vs ₹1,504.24 (Q1 FY26)
Net Profit: ₹253.93 (Q1 FY27) vs ₹132.36 (Q1 FY26) - 91.8% YoY increase
- Attributable to Owners of the Company: ₹245.30
- Attributable to Non-controlling interests: ₹8.63
EPS: ₹83.32 (Basic and Diluted)
Quarterly comparison:
- Revenue from Operations: ₹1,847.95 (Q1 FY27) vs ₹1,670.07 (Q4 FY26)
- Net Profit: ₹253.93 (Q1 FY27) vs ₹211.12 (Q4 FY26)
Full year reference (FY26):
- Revenue from Operations: ₹6,273.54
- Net Profit: ₹689.39
Segment-wise Performance:
The Group reported segment information under three segments:
1. Life Science Chemicals (Active pharmaceutical ingredients and its intermediates, crop protection chemicals)
2. Performance and Other Chemicals (Adhesion promoters, bulk chemicals, epoxy resins and hardeners, intermediates, textile dyes)
3. Others (Agribiotech, food products, services and others)
Q1 FY27 Segment Results:
- Life Science Chemicals: ₹92.78 crore
- Performance and Other Chemicals: ₹239.83 crore
- Others: ₹6.77 crore
- Total Segment Results: ₹339.38 crore
Q1 FY27 Segment Revenue:
- Life Science Chemicals: ₹682.56 crore
- Performance and Other Chemicals: ₹1,094.56 crore
- Others: ₹70.83 crore
- Total Segment Revenue: ₹1,847.95 crore
Corporate Actions:
Dividend: Not specified
Share split/bonus/buyback: Not specified
Capital raising: Not specified
Other Significant Information:
Employee benefit expenses for Q4 FY26 included impact of reassessment of past service cost on gratuity and remeasurement of leave encashment due to implementation of new labour code, resulting in gain of ₹24.38 crore (standalone) and ₹25.41 crore (consolidated) due to reversal of excess provision
Figures for Q4 FY26 are balancing figures between audited figures for full financial year and published year-to-date figures up to third quarter
Consolidation includes 43 subsidiaries, 1 associate, 2 joint ventures, and 1 joint operation
3 subsidiaries with total revenues of ₹283.27 crore and net profit of ₹13.42 crore were reviewed by other auditors
36 subsidiaries with total revenues of ₹75.47 crore and net profit of ₹10.66 crore were not reviewed by their auditors but are not material to the Group